Study S002358

A Phase 1, Repeated Single-Dose, Double Blind, Randomized, Five Treatment Controlled Safety and Pharmacological Response Evaluation Trial of MKC253 Inhalation Powder in Adult Male and Postmenopausal Female Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT00642538
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 20
Start: 2008-02
Primary completion: 2008-09
Lead sponsor: Mannkind Corporation
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:MKC253 Inhalation Powder; DRUG:Technosphere Inhalation Powder; DRUG:subcutaneous injection
Results posted: FALSE
Secondary identifiers: OTHER:EudraCT #: 2007-003430-42

Registered primary outcomes

AUC 0-240 min post-prandial serum glucose [240 minutes]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.